German AMNOG reform fails to hit the mark
This article was originally published in SRA
Executive Summary
Reform of Germany's controversial early benefit assessments for new medicines is currently under discussion, but the changes floated look unlikely to solve any of the main issues that are frustrating pharmaceutical companies. During a recent debate in the German parliament, industry made little progress on ensuring that rebates remain confidential, and nothing is likely to change on the thorny issue of comparators, according to Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and Brussels representative for the BPI, which represents small- and medium-sized companies in Germany.